{"title":"多粘菌素 B 血液灌流治疗败血症的疗效。","authors":"Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava","doi":"10.5005/jp-journals-10071-24805","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.</p><p><strong>Materials and methods: </strong>Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (<i>n</i> = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (<i>n</i> = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.</p><p><strong>Results: </strong>Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.</p><p><strong>Conclusion: </strong>Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.</p><p><strong>How to cite this article: </strong>Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.</p>","PeriodicalId":47664,"journal":{"name":"Indian Journal of Critical Care Medicine","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471987/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.\",\"authors\":\"Indranil Ghosh, Sukhwinder Sangha, Gaurav Pandey, Atul Srivastava\",\"doi\":\"10.5005/jp-journals-10071-24805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.</p><p><strong>Materials and methods: </strong>Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (<i>n</i> = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (<i>n</i> = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.</p><p><strong>Results: </strong>Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.</p><p><strong>Conclusion: </strong>Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.</p><p><strong>How to cite this article: </strong>Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.</p>\",\"PeriodicalId\":47664,\"journal\":{\"name\":\"Indian Journal of Critical Care Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471987/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10071-24805\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10071-24805","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的：研究多粘菌素 B 血液灌流治疗败血症的疗效：研究多粘菌素B血液灌流在脓毒症治疗标准护理之外的疗效：将 50 名脓毒症患者（平均年龄为 54.26 ± 14.64 岁；68% 为男性）随机分为病例组（n = 25；在接受标准重症监护室护理的同时接受多粘菌素 B 血液灌流）或对照组（n = 25；仅接受标准重症监护室护理）。每隔 6、12、24、48 和 72 小时对患者进行一次随访。最后一次随访在第 7 天进行。记录了重症监护室的住院时间和第 7 天前的存活率。同时还记录并比较了临床和生化指标的变化：结果：病例和对照组入院时的器官功能衰竭顺序评估（SOFA）平均得分分别为 3.44 ± 1.00 和 2.80 ± 0.82。与对照组相比，病例的病情改善更快、更持久。两组患者在第 7 天的死亡率无明显差异：结论：多粘菌素 B 血液灌流可使重症监护室收治的脓毒症患者更快康复，并有降低死亡率的非显著趋势：Ghosh I, Sangha S, Pandey G, Srivastava A. 多粘菌素B血液灌流治疗败血症的疗效。Indian J Crit Care Med 2024;28(10):930-934.
Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis.
Objectives: To study the efficacy of polymyxin B hemoperfusion in addition to standard care for sepsis treatment.
Materials and methods: Fifty sepsis patients (mean age 54.26 ± 14.64 years; 68% males) were randomized to either the case group (n = 25; receiving Polymyxin B hemoperfusion in addition to standard ICU care) or the control group (n = 25; receiving standard ICU care only). The patients were followed up at frequent intervals of 6, 12, 24, 48, and 72 hours. A last follow-up on day 7 was done. The duration of the ICU stay and survival until day 7 were recorded. Changes in clinical and biochemical parameters were also noted and compared.
Results: Mean sequential organ failure assessment (SOFA) scores at admission were 3.44 ± 1.00 and 2.80 ± 0.82, respectively, in cases and controls. Cases as compared to controls showed faster, and sustainable improvement. No significant difference between the two groups was seen for mortality at day 7.
Conclusion: Polymyxin B hemoperfusion tends to show a faster recovery and a non-significant trend towards reduced mortality in ICU-admitted sepsis patients.
How to cite this article: Ghosh I, Sangha S, Pandey G, Srivastava A. Efficacy of Polymyxin B Hemoperfusion for Treatment of Sepsis. Indian J Crit Care Med 2024;28(10):930-934.
期刊介绍：
Indian Journal of Critical Care Medicine (ISSN 0972-5229) is specialty periodical published under the auspices of Indian Society of Critical Care Medicine. Journal encourages research, education and dissemination of knowledge in the fields of critical and emergency medicine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
